GLP-1 Receptor Agonists

Semaglutide (GLP-1 Receptor Agonist)

For Research Use Only. Not for Human or Veterinary Use.

Overview

Semaglutide (development code NN9535) is a synthetic analogue of human GLP-1 that acts as a selective, long-acting GLP-1 receptor agonist. It carries two substitutions from native GLP-1 — an Aib residue at position 8 for resistance to the DPP-4 enzyme, and an Arg substitution — plus a C18 fatty-diacid on Lys26 for albumin binding, which extends its half-life to about seven days. It is the most heavily published GLP-1 receptor agonist in the research literature and is studied by both subcutaneous and oral routes.

Chemical Profile

PropertyValue
CAS number910463-68-2
Development codeNN9535
ClassSelective GLP-1 receptor agonist
Backbone31-amino-acid GLP-1 analogue; Aib at position 8; C18 fatty-diacid at Lys26
Molecular formulaC₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight4113.58 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
Semaglutide at a glance
Class
Selective GLP-1 receptor agonist
Originator
Novo Nordisk
Research status
Most-published GLP-1 agonist
Study route
Subcutaneous (weekly) or oral (daily)
Half-life
≈ 7 days
Key feature
DPP-4-resistant, long-acting GLP-1 analogue

Mechanism of Action

Semaglutide selectively activates the GLP-1 receptor, a class-B GPCR that signals through Gαs to raise cAMP. The Aib substitution blocks the DPP-4 cleavage that rapidly inactivates native GLP-1, and the fatty-diacid chain binds albumin — together these give the long half-life. Beyond glucose handling, GLP-1R signalling is also studied in cardiovascular and central-nervous-system contexts.

ComponentDetail
Primary targetGLP-1 receptor (GLP-1R)
Receptor classClass B G-protein-coupled receptor
G-protein couplingGαs → adenylyl cyclase → cAMP
Downstream signallingPKA, EPAC2, CREB, PI3K/Akt, MAPK/ERK
DPP-4 resistanceAib at position 8 blocks enzymatic inactivation
EffectStudied mechanism
Glucose-dependent insulin secretionGLP-1R activation in pancreatic β-cells
Glucagon suppressionGLP-1R activation in α-cells
Delayed gastric emptyingVagal GLP-1R signalling
Appetite suppressionGLP-1R in the hypothalamic arcuate nucleus
Cardiovascular / neuro researchGLP-1R in myocardium and CNS (emerging areas)

Pharmacology

ParameterValue
Half-life (t½)≈ 7 days (~165–168 h)
Time to peak (Tmax)12–24 h (SC); 1–3 h (oral)
Bioavailability≈ 89% (SC); ≈ 1% (oral)
Volume of distribution≈ 0.3 L/kg
Protein binding≈ 99% (albumin)
MetabolismProteolytic degradation (no CYP involvement)
EliminationRenal (peptide fragments) and fecal

Research Evidence

Semaglutide has one of the largest evidence bases of any peptide. Representative studies and trial programs are named below with their research focus; specific numerical outcomes are not restated here as claims.

Preclinical modelResearch focusReference
Enzyme-stability / design studiesAlbumin binding and half-life extensionLau J, et al. (2015)
Rodent brain mappingArcuate-nucleus GLP-1R and appetiteSecher A, et al. (2014)
Diabetic rodent modelsGlycemic and body-weight effectsKapitza C, et al. (2017)
Clinical programPhaseResearch focusReference
SUSTAIN programPhase 3Glycemic control in type-2-diabetes researchSUSTAIN trials
SUSTAIN-6Phase 3bCardiovascular outcomesMarso SP, et al. (2016), NEJM
STEP programPhase 3Body-weight endpoints in obesity researchWilding JPH, et al. (2021), NEJM
PIONEER / SELECTPhase 3Oral route; cardiovascular outcomesSemaglutide clinical program

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
~15% mean body-weight reduction at 2.4 mgSTEP-1 obesityWilding JPH et al., NEJM 2021
Reduced major adverse cardiovascular eventsSUSTAIN-6 / SELECTMarso SP et al., NEJM 2016
Appetite suppression via hypothalamic GLP-1Rrodent brain mappingSecher A et al., 2014

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dosing range (literature)0.25–2.4 mg, once weekly (SC), in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Final concentration≈ 1–2.5 mg/mL
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~14 days
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published safety observations for the compound, provided as research reference only. This material is not for human or veterinary use.

CategoryPublished observations
Most commonGastrointestinal: nausea, diarrhea, vomiting, constipation (dose-dependent)
Serious (rare)Pancreatitis, gallbladder disease, retinopathy-related events at low frequency
CardiovascularModest heart-rate increase; reduced events reported in outcome trials
Rodent findingThyroid C-cell findings in rodent studies
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble (> 50 mg/mL)
logP (octanol/water)≈ 4.5–5.0
Isoelectric point (pI)≈ 4.7
pH (reconstituted)7.0–8.0
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

Semaglutide is made by solid-phase peptide synthesis of the 31-residue analogue, with the C18 fatty-diacid installed on the Lys26 side chain after selective deprotection. It is shorter than the dual/triple agonists but the fatty-acid conjugation and preparative purification are still the defining steps.

StepDetail
StrategySolid-phase peptide synthesis, Fmoc/tBu chemistry
ResinRink amide MBHA resin
CouplingHATU / HBTU with DIPEA
Fatty-acid conjugationC18 diacid coupled to Lys26 side chain after selective (Mtt) deprotection
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18, ACN/H₂O + 0.1% TFA gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. Confirm the C18 fatty-diacid on Lys26 and the Aib substitution.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, 20–60% B over 25 minSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 4114 Da (multiply charged +3 to +7)
MALDI-TOFMass confirmation[M+H]⁺ ≈ 4114 Da (multiply charged +3 to +7)
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: 20–60% B over 25 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 4114 Da (multiply charged +3 to +7)). Confirm the C18 fatty-diacid on Lys26 and the Aib substitution.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: Confirm the C18 fatty-diacid on Lys26 and the Aib substitution.

Selected References

  • Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. Journal of Medicinal Chemistry, 2015.
  • Secher A, et al. The arcuate nucleus mediates GLP-1 receptor agonist–induced weight loss. Journal of Clinical Investigation, 2014.
  • Marso SP, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). New England Journal of Medicine, 2016.
  • Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). New England Journal of Medicine, 2021.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS; endotoxin tested by LAL
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need Semaglutide — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote